Phase I/II storm study: Intravenous delivery of a novel oncolytic immunotherapy agent, Coxsackievirus A21, in advanced cancer patients. (4th November 2015) - Pandha, Hardev; Harrington, Kevin; Ralph, Christy; Melcher, Alan; Grose, Mark; Shafren, Darren